Clinical trials: Graves' Ophthalmopathy
Graves Orbitopathy, Hyperthyroidism
Development of a Non-Invasive Prognostic Test for Graves Orbitopathy
The aim of this research project is to develop a non-invasive, simple, robust, and sensitive prognostic test that can identify hyperthyroidism patients who are at risk of developing Graves' Orbitopathy.
- Trial name
- GoPro (NCT07472062)
- Testing
- Schirmer's test
- Where
- Belgium
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Graves' Disease
Randomized Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy
OBJECTIVES: I. Evaluate the effects of 20 Gy of external-beam radiotherapy to 1 orbit vs. the untreated orbit at 3 and 6 months after therapy in patients with Graves' ophthalmopathy. II.
- Trial name
- NCT00004660
- Testing
- Radiotherapy
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Graves Disease, Hyperthyroidism
Remission Induction and Sustenance in Graves' Disease 2
ATD therapy for Graves' disease is one of the commonly used options for therapy of the hyperthyroidism. The investigators study how to optimally keep patients in remission.
- Trial name
- NCT00796913
- Testing
- Stop medication
- Volunteers
- 139 people
- Sponsor
- Aalborg University Hospital
Thyroid Eye Disease
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).
- Trial name
- REVEAL-1 (NCT06625411)
- Testing
- VRDN-003
- Where
- 48 sites in United States, Germany and 3 more
- Volunteers
- 132 people
- Sponsor
- Viridian Therapeutics, Inc.
Graves' Disease
Application of Digital Infrared Thermal Imaging (DITI) in Graves' Disease
Graves' disease is characterized by thyrotoxicosis, goiter, ophthalmopathy and dermopathy. Pathogenesis involves autoimmune process. The investigators think temperatures of the area involved in the inflammation may change.
- Trial name
- NCT01182584
- Where
- Taiwan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Thyroid Eye Disease, Graves' Orbitopathy
Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease
This is an expanded access protocol intended to provide access to teprotumumab for the treatment of up to 60 patients in the United States with active moderate to severe thyroid eye disease where there is no comparable or…
- Trial name
- EAP (NCT04040894)
- Testing
- Teprotumumab
- Where
- 8 sites in United States
- Sponsor
- Amgen
Thyroid Eye Disease
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.
- Trial name
- NCT06248619
- Testing
- Teprotumumab
- Where
- 38 sites in United States, Argentina and 9 more
- Volunteers
- 89 people
- Sponsor
- Amgen
Graves Disease, Graves Ophthalmopathy
Liver Function After Intravenous Methylprednisolone Administration
Graves' orbitopathy (GO) is a characterized by orbital soft tissue inflammation and oedema associated with glycosaminoglycan deposition and fibrosis. The most frequent cause is Graves' disease.
- Conditions
- Graves Disease, Graves Ophthalmopathy, Liver Diseases, Liver Failure
- Trial name
- NCT03667157
- Testing
- every week IVMP therapy, very high doses IVMP therapy
- Volunteers
- 68 people
- Sponsor
- Medical University of Warsaw
Graves Disease (Basedow's Disease)
Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance
The aim of our study is to compare in a randomized multicentric study the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation (experimental arm) compared to a conventional approach based on the…
- Trial name
- NCT01295333
- Testing
- the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation, The initiation of LT4 as soon as the first biological signs of hypothyroidism.
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Graves Disease
Incidence of Graves' Disease After COVID-19 Vaccination
It is well known that an infection can be a triggering factor for the development of autoimmune thyroid disease. The COVID-19 pandemic was an example of this, with several reports of both subacute thyroiditis as well as Graves'…
- Trial name
- NCT07213141
- Testing
- Data extraction
- Where
- 3 sites in Belgium
- Volunteers
- 161 people
- Sponsor
- Laura ICONARU
Thyroid, Thyroid Cancer
Three-dimensional Ultrasonography Thyroid Volume Measurement.
The purpose of this clinical trial is to investigate the accuracy of applying three-dimensional ultrasound on thyroid gland patients when determining a gland volume.
- Conditions
- Thyroid, Thyroid Cancer, Thyroid Diseases, Graves Disease
- Trial name
- NCT05510609
- Testing
- BK 5000 Ultrasound Machine
- Where
- Denmark
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Thyroid Eye Disease
Study of ZB001 in Chinese Patients With Thyroid Eye Disease
The investigational drug, ZB001 is a humanized IgG1κ monoclonal antibody targeting human IGF-1R. The study is designed to evaluate the efficacy, safety, tolerability, and pharmacokinetics（PK）/pharmacodynamics (PD) profile of…
- Trial name
- NCT05776121
- Testing
- ZB001 for injection
- Where
- 9 sites in China
- Volunteers
- 17 people
- Sponsor
- Zenas BioPharma (USA), LLC
Thyroid Neoplasms, Goiter, Nodular
Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy
We aim to study the effect of local anesthetic when used in conjunction with general anesthesia during thyroidectomy or parathyroidectomy.
- Conditions
- Thyroid Neoplasms, Goiter, Nodular, Thyroid Nodule, Graves' Disease
- Trial name
- NCT02205801
- Testing
- Superficial Cervical Plexus Block, Local Wound Infiltration, 0.9% saline
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Chicago
Thyroid Eye Disease
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
- Trial name
- NCT05517421
- Testing
- Batoclimab
- Where
- 93 sites in United States, Canada and 7 more
- Volunteers
- 114 people
- Sponsor
- Immunovant Sciences GmbH
Graves' Ophthalmopathy
Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy and in Normal People
Find if the retinal function is affected in both the nonsevere and the severe stage of Graves' ophthalmopathy (GO) by comparing the retinal oxygen saturation of GO patients with that of normal people.
- Trial name
- NCT02290704
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Thyroid Eye Disease
TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study
This is a double-masked, randomized, parallel-assignment, multicenter trial examining the safety and tolerability of teprotumumab in the treatment of Thyroid Eye Disease (TED) in adult participants.
- Trial name
- NCT05002998
- Testing
- Teprotumumab
- Where
- 28 sites in United States, France and 4 more
- Volunteers
- 313 people
- Sponsor
- Amgen
Graves' Orbitopathy
A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy
Graves' disease (GD) is the most frequent cause of hyperthyroidism in iodine sufficient countries and Graves' orbitopathy (GO) is its most common extrathyroidal manifestation.
- Trial name
- ABLAGO (NCT04776993)
- Testing
- Methimazole, Radioiodine or thyroidectomy
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- University of Pisa
Graves´ Disease
A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China
This study was a prospective follow-up study of newly diagnosed and relapsed Graves' disease patients in the Endocrinology Clinic of the First Affiliated Hospital of China Medical University.
- Trial name
- NCT07040306
- Testing
- Methimazole(MMI)
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- First Hospital of China Medical University
Type 1 Diabetes, Hashimoto Disease
Telehealth Music Therapy for Adults With Endocrine Disorder and Depression
The goal of this clinical trial is to explore if a telehealth music therapy intervention helps with quality of life, depression symptoms, anxiety symptoms. It will also explore the participants' relationship to music.
- Conditions
- Type 1 Diabetes, Hashimoto Disease, Graves Disease, Addison Disease
- Trial name
- NCT07413874
- Testing
- Telehealth Resource Oriented Music Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Appalachian State University
Graves´ Disease
Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study)
AGO study - adjuvant treatment, with NSAID, of endocrine ophthalmopathy in Graves´ disease Background - Already at diagnosis of Graves disease approximately 98% of the patients have morphological changes of the retrobulbar tissue…
- Trial name
- aGO (NCT01458600)
- Testing
- Diclofenac, Methimazole, L-thyroxin
- Where
- 3 sites in Sweden
- Volunteers
- 65 people
- Sponsor
- Mikael Lantz